Kinneret Savitsky - BioLine Rx Insider

CEO, Director

Dr. Kinneret Savitsky will no longer serve as Chief Executive Officer at BioLine Rx Ltd effective October 10 2016. She has held this role since January 2010. Prior to that she was General Manager of BioLine Innovations Jerusalem Ltd. since 2004. Dr. Savitsky was formerly Vice President Biology Research and Development at Compugen a biotechnology company. She joined Compugen in 1997 as Senior Scientist in Compugen newly founded laboratory and led the company shift from computational genomics to development of diagnostics and therapeutics. She was responsible for all of Compugen drug candidate identification and development as well as experimental biology. At Compugen she managed a team of over 35 scientists and drug developers
Age: 48  CEO Since 2010      
972 8 642 9100
Savitsky holds a BS degree in Biology from The Hebrew University of Jerusalem, a MS degree in Human Genetics and a Doctorate of Science degree in Human Genetics, both from TelAviv University.

Management Efficiency

The company has return on total asset (ROA) of (20.85) % which means that it has lost $20.85 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (34.07) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 365 K in total debt with debt to equity ratio (D/E) of 0.01 which may suggest the company is not taking enough advantage from borrowing. BioLine Rx Ltd has Current Ratio of 11.48 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, inlicensing, and developing therapeutic candidates that address unmet medical needs. BioLine Rx Ltd (BLNEF) is traded on OTC Market in USA. It is located in Modi?in, and employs 48 people.

Did you try this?

Run Correlation Analysis Now

Correlation Analysis

Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Hide  View All  NextLaunch Correlation Analysis
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add BioLine Rx Ltd to your portfolio

Top Management

BioLine Rx Ltd Leadership Team
Sandra Panem, Director, Ph.D
Leah Klapper, Executive
Philip Serlin, COO
Avraham Molcho, Director, MBA
Moshe Phillip, President, Ph.D
Aharon Schwartz, Chairman
Mali Zeevi, Director, CPA
Jacob Friedman, Director, MBA
Arnon Aharon, President
Kinneret Savitsky, CEO
Merril Gersten, Executive
Michael Anghel, Director, MBA
David Malek, President
Raphael Hofstein, Director
Nurit Benjamini, Director, MBA

Stock Performance

BioLine Rx Performance Indicators